The inMIND study was a global, double-blind, randomized, placebo-controlled phase 3 study in patients with relapsed or refractory follicular lymphoma after at least one prior therapy.[5] Patients were treated with a combination of rituximab and lenalidomide with the addition of tafacitamab or placebo.[5] The addition of tafasitamab resulted in an increase in median progression-free survival from 13.9 months in the placebo group to 22.4 months in the tafasitamab group.[5][3] This corresponded to a 57% reduction in the risk of progression, relapse or death (hazard ratio 0.43; 95% CI 0.32–0.58; p<0.0001).[5][3] The safety profile of the combination with tafasitamab was acceptable and met expectations for this patient population.[5][4] There were no directly treatment-related deaths in the tafasitamab group, while there were two such deaths (1%) in the placebo group.[5] The authors interpreted that this triple combination provides a statistically significant and clinically important improvement in progression-free survival and represents a potential new standard of care for this diagnosis.[5]